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Sterile injury can cause a systemic inflammatory response syndrome (SIRS) that resembles the host response during sepsis. The
inflammatory response following trauma comprises various systems of the human body which are cross-linked with each other
within a highly complex network of inflammation. Endogenous danger signals (danger-associated molecular patterns; DAMPs;
alarmins) as well as exogenous pathogen-associated molecular patterns (PAMPs) play a crucial role in the initiation of the
immune response. With popularization of the “danger theory,” numerous DAMPs and PAMPs and their corresponding pathogen-
recognition receptors have been identified. In this paper, we highlight the role of the DAMPs high-mobility group box protein 1
(HMGB1), interleukin-1α (IL-1α), and interleukin-33 (IL-33) as unique dual-function mediators as well as mitochondrial danger
signals released upon cellular trauma and necrosis.
1. Introduction
Trauma and tissue damage trigger an inflammatory response,
which is required for postinjury regeneration and tissue
repair. In the case of severe trauma, an overwhelming, sys-
temic inflammatory response can result in additional multi-
organ damage to the host cells and the development of multi-
organ failure (MOF) [1]. The inflammatory response after
severe trauma correlates with the severity of injury and is
associated with mortality and the development of complica-
tions, such as MOF or sepsis [2, 3]. Inflammation following
tissue damage is a dynamic process, which is driven by
numerous inflammatory mediators. The innate and the
adaptive immune system can be activated by endogenous sig-
nals that originate from stressed, injured, or necrotic cells,
signifying “danger” to the host [4]. The notion that endoge-
nous and exogenous molecular patterns can cause a similar
host response through the same receptors challenged the
model of the immune system discriminating between “self”
and “nonself”, but could be suﬃciently explained by the
“danger theory.” In 1994, the “danger theory” of the inflam-
matory response following trauma or infection has been
introduced and has meanwhile significantly broadened our
understanding of the immune response [4–6]. Endogenous
danger signals released from necrotic or stressed cells which
trigger the inflammatory response after trauma have been
termed alarmins or danger-associated molecular patterns
(DAMPs) [6, 7]. Initially, it was believed that apoptotic cells
are not a source for DAMPs, but it became meanwhile
evident that DAMPs can also be released during a specific
modality of programmed cell death, referred to as immuno-
genic apoptosis [8–10]. DAMPs share structural and func-
tional similarities with exogenous, conserved microbial
surface structures released from invading microorganisms,
so-called pathogen-associated molecular patterns (PAMPs),
which, like DAMPs, are recognized by a set of receptors,
termed pathogen-recognition receptors (PRRs) [4, 11–15].
However, this definition of DAMPs is not always used consis-
tently, and sometimes endogenous alarmins and exogenous
PAMPs are collectively classified as danger-associated molec-
ular patterns (DAMPs) [6].
Well-known alarmins include but are not limited to
heat shock proteins (Hsp), hyaluronan, uric acid (UA,
monosodium urate), galectins, thioredoxin, adenosine, high-
mobility group box protein 1 (HMGB1), interleukin-1α (IL-
1α), and interleukin-33 (IL-33) [6]. As unique features,
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HMGB1, IL-1α, and IL-33 exert dual functions as intracel-
lular transcription factors and as extracellular inflammatory
mediators.
In this paper, we focus on the role of the dual function
DAMPs in the initiation of the immune response after
trauma. Moreover, we shed light on recently discovered
mechanisms of activation of innate immunity by mitochon-
drial DAMPs released from disrupted cells which bear
bacterial molecular motifs similar to PAMPs due to their
endosymbiotic origin.
2. High-Mobility Group Box Protein 1
HMGB1 was originally described as a DNA-binding nuclear
protein that acts as a transcription factor [16]. A decade
ago, HMGB1 has been rediscovered as a proinflammatory
cytokine in sepsis and endotoxemia which, under these con-
ditions, is released downstream of the early cytokine produc-
tion [17]. Meanwhile, HMGB1 has emerged as a prototypical
DAMP and has been shown to play an important role in the
response to sterile injury, such as hemorrhagic shock and
ischemia/reperfusion injury [18]. As a ubiquitous protein,
HMGB1 is virtually expressed by all cell types with a nucleus.
HMGB1 can be released by active secretion predomi-
nantly from macrophages and monocytic cells but also from
other cell types that are exposed to proinflammatory
cytokines or bacterial products [19]. Besides PAMPs and
cytokines, active HMGB1 secretion from monocytes can be
triggered by the complement activation product C5a [20].
This mechanism not only seems to play a role in sepsis but
also in sterile injury since in patients with severe trauma
levels of HMGB1 correlate with the extent of complement
activation [21]. Interestingly, active HMGB1 secretion is
controlled by the autonomic nervous system as activation
of the cholinergic anti-inflammatory pathway suppresses
HMGB1 secretion from macrophages [22]. In this context, it
has been postulated that the spleen is an abundant source for
HMGB1 and that mediator secretion by splenic macrophages
in the red pulp is under influence of the vagus nerve [23, 24].
In its role as an endogenous danger signal, passive release
of HMGB1 from necrotic or disrupted cells stimulates innate
immunity, while it was initially believed that HMGB1 is
not released from apoptotic cells [16]. However, recent
research revealed that after initial nuclear retention in
apoptotic cells HMGB1may be released during late apoptosis
(secondary necrosis) due to increased cellular permeability
and nucleosomal degradation [25].
When actively released by macrophages, HMGB1 under-
goes posttranslational modifications, including acetylation,
phosphorylation, and methylation [25–27]. Moreover, post-
translational redox modifications of certain cystein residues
regulate the activity of (actively and passively released)
HMGB1, including receptor interaction and subsequent sig-
naling events [25, 28]. The redox sensitivity of HMGB1 has
particular ramifications for systemic inflammation and
sepsis with increased oxidative stress and release of reactive
oxygen species (ROS). Oxidation of HMGB1 not only occurs
in necrotic cells but also during apoptosis, which is associated
with generation of ROS by mitochondria [29]. On the
other hand, HMGB1 can promote the production of ROS
in neutrophils [30]. It has been postulated that oxidation
might temporarily inactivate HMGB1, and in turn, the
activity of HMGB1 is prolonged andmaintained in a reduced
environment [29, 31].
With respect to its functional roles in inflammation,
HMGB1 exerts pleiotropic proinflammatory eﬀects on var-
ious organ systems. These eﬀects include activation of
phagocytic and endothelial cells and the loss of epithelial
barrier functions, resulting in typical signs of inflammation
and other symptoms, collectively referred to as “sickness syn-
drome” [32, 33]. In addition, HMGB1 promotes processes
required for host defense, tissue repair, and regeneration,
including chemotaxis, angiogenesis, maturation of dendritic
cells, and recruitment and proliferation of stem cells [34].
Other reports suggest that HMGB1 amplifies the inflam-
matory response by binding endogenous and exogenous
inflammatory mediators, such as cytokines or endotoxins
[35, 36]. In fact, the intrinsic capacity of HMGB1 to trigger
immune responses has been questioned lately since recombi-
nant HMGB1 failed to induce cytokine production in vitro.
A possible explanation for these conflicting results might
be the redox state of cysteine residues since commercially
available preparations of HMGB1 may contain reducing
agents [25]. In the case of formation of HMGB1-containing
immunostimulatory complexes, it has been suggested that
inflammation is primarily promoted through the receptor
of the partner molecule in independence of the redox state
of HMGB1 [25, 37]. However, to date only limited informa-
tion is available about the mechanisms, kinetics, and confor-
mational changes involved in HMGB1-complex formation.
The activities of HMGB1 are mediated through interac-
tion with pathogen-recognition receptors, which also recog-
nize products from invading microorganisms. HMGB1 has
been shown to be a ligand of various toll-like receptors and to
signal through TLR2 and TLR4, the latter being required for
HMGB1-mediated activation of macrophages and the devel-
opment of secondary damage in ischemia/reperfusion injury
[18, 38–40]. In addition to TLRs, HMGB1 interacts with the
receptor for advanced glycation endproducts (RAGE) on a
variety of cell types which is involved in the initiation of a
rapid and sustained inflammatory response as well as in
mediating the chemotactic and mitogenic activities of
HMGB1 [6, 41, 42].
However, RAGE not only senses and transmits danger
upon HMGB1 release but also contributes to inactivation or
neutralization of HMGB1 in form of soluble RAGE, which
is released simultaneously to HMGB1 in severe trauma [43,
44]. But it is also conceivable that soluble RAGE functions as
a carrier to convey HMGB1 activities to remote tissues/cells,
as it has been suggested for various cytokines, although
this putative mechanism of action currently lacks direct
evidence. Binding of HMGB1 to thrombomodulin on
endothelial cells represents another mechanism by which
HMGB1-triggered inflammation can be attenuated [45].
On the other hand, interference of HMGB1 with the
thrombin-thrombomodulin complex may inhibit the anti-
inflammatory protein-C pathway. Furthermore, HMGB1
can drive coagulation towards a procoagulatory state by
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stimulating tissue factor expression and inhibiting tissue
plasminogen activator on endothelial cells, putatively paving
the way for the development of manifest coagulopathy and
disseminated intravascular coagulation [46].
The knowledge about HMGB1 as an inflammatorymedi-
ator gained during the last decade after its rediscovery is
mainly based on results from experimental studies, with
models of sepsis and endotoxemia in particular. In the setting
of experimental sepsis, HMGB1 has been defined as a late
mediator, as compared to other cytokines, such as IL-6
and TNF-α [17]. Antibody-induced neutralization or use of
recombinant A box domain of HMGB1 (antagonist of B box
proinflammatory activity) in sepsis could improve the
outcome, even when applied after the onset of disease [17,
47, 48]. Other preclinical models, in which blockade of
HMGB1 led to promising results, include arthritis, ischemic
brain injury, liver injury, and organ transplantation [25].
In severe trauma in humans, HMGB1 acts as an early
proinflammatory mediator, which is systemically released
within 30 to 60 minutes, peaking from 2 to 6 hours after
injury [21, 49]. The concentration of HMGB1 correlates
with the severity of injury and the systemic inflammatory
response. Moreover, patients who develop organ dysfunction
and nonsurvivors of severe trauma show higher levels of
HMGB1 [21]. In a conflicting report, no correlation between
increased HMGB1 levels after trauma and injury severity or
parameters of patient outcome was found, which might be
due to a rather small sample size in the latter study [49].
However, there are striking diﬀerences in the absolute values
of HMGB1 concentrations measured in the patient popu-
lations of both studies, which may reflect the diﬃculty in
HMGB detection. As amatter of fact, current standard detec-
tion assays do not distinguish between diﬀerent forms of
HMGB1 as a result of posttranslational changes, redox reac-
tions, or complex formation [25]. In contrast to sterile injury,
the peak of HMGB1 release during sepsis occurs during
later stages of the disease, and the levels of HMGB1 do not
always decrease in patients who have recovered from sepsis
[17, 50]. Although neutralization of HMGB1 has been pro-
tective against tissue injury in numerous preclinical models
of inflammatory diseases, the complexity of its mechanisms
of action currently precludes the clinical use of HMGB1-
neutralizing agents, and clinical studies targeting HMGB1
have not been performed at present.
Owing to its pleiotropic proinflammatory activities,
HMGB1 still represents a promising therapeutic target
in various inflammatory conditions. However, targeting
HMGB1 for protection in sterile injury and infection-asso-
ciated inflammation in the clinical setting requires thorough
understanding of the underlying molecular mechanisms.
3. Interleukin-1α
The interleukin 1 family (IL-1F) currently consists of 11
known members [51]. Their eﬀects in inflammation are
complex as they have anti-inflammatory as well as proin-
flammatory properties. In general, IL-1 activates lympho-
cytes, enhances the defensive activity of monocytes and
macrophages by inducing the production of inflammatory
mediators, and acts as costimulant on natural killer cells [52].
IL-1 is divided into 2 subtypes, IL-1α and IL-1β. IL-1β is the
most thoroughly investigated member of the IL-1F due to
its role in autoimmune diseases [53]. Interleukin-1 receptor
antagonist (IL-1Ra) is a specific inhibitor of IL-1α and IL-
1β on their membrane-bound receptor IL-1R, and generic
IL-1Ra is routinely used in the treatment of patients with
rheumatoid arthritis [54].
IL-1α belongs to the group of dual function alarmins
(formerly also known as endokines), describing the ability to
induce an inflammatory response upon release by necrotic
cells besides intracellular functions in intact cells [7]. In con-
trast to IL-1β, IL-1α is constitutively expressed in epithelial
cells, keratinocytes, and fibroblasts. Its precursor molecule
(pIL-1α) is also biologically active.
Cells constitutively expressing IL-1α rarely secret it in
an active manner. From these cells, IL-1α is only released
after loss of cellular integrity. In contrast, monocytes and
macrophages do not constitutively express IL-1α but are
capable of de novo synthesizing IL-1α. Upon activation of
monocytic cells, membrane calpain is activated to cleave pIL-
1α, followed by secretion of IL-1α. In contrast to cellular
necrosis, IL-1α remains attached to chromatin during apop-
tosis, which reduces its intracellular mobility and possibly
limits its passive release [55]. Thus, IL-1α is predominantly
released by necrotic cell disintegration, but stays intracellular
under physiological conditions, during apoptosis, and even
in the presence of inflammatory diseases [56–59]. As men-
tioned above, the precursor can be cleaved by membrane-
bound calpain, a calcium-activated cysteine protease, which
is not found in all cell types expressing pIL-1α [60]. Both
the uncleaved (pIL-1α) and the mature form of IL-1α can
bind to the IL-1R, but membrane-bound IL-1α can also exert
juxtacrine functions in a receptor-independent manner [61].
Like IL-33 (see below) but unlike other members of the IL-
1F, IL-1α not only acts on intra- or extracellular membrane
receptors but also as a nuclear transcription factor [62].
While pIL-1α contains the sequence for the nuclear localiza-
tion site, the mature form (IL-1α) has no ability to function
as a transcription factor [63]. In cultured resting cells, pIL-
1α is distributed evenly in the cytoplasm. After exposition
to inflammatory stimuli, such as lipopolysaccharides (LPS)
or TNFα, pIL-1α locates to the nucleus without further pro-
cessing and acts as a transcription factor. This leads to the IL-
1R-independent production of NF-κB and proinflammatory
cytokines, such as IL-6 and IL-8 [63]. However, the biological
role of constitutively expressed IL-1α is not entirely clear. In
unstimulated cells expressing IL-1α, large amounts of intra-
cellular IL-1Ra are present at the same time, competing for
binding sites [64]. IL-1α has a costimulatory eﬀect on T-cell
function and is expressed consistently by thymic epithelial
cells, but mice deficient of IL-1α show normal antibody
production and proliferation [51, 65]. The expression of
interferon-γ largely depends on IL-1α and antibodies to IL-
1α but not IL-1β block its activity [66]. Antibodies to IL-
1α inhibited the immune response in sterile inflammation in
mice, corroborating its role as an alarmin [67]. Interestingly,
mesothelial cells have been proposed to play a key role
in sensing cell death. Exposed to recombinant IL-1α, they
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produce CXCL-1, a cytokine with neutrophil attractant
properties [68, 69]. The intraperitoneal injection of lysed
cells in vivo leads to neutrophil infiltration that is markedly
reduced in CXCR2- (receptor to CXCL-1-) deficient mice.
The CXCL-1 production following exposure to cytosolic
extracts of necrotic tissues can be abolished by IL-1Ra or
in IL-1α-deficient in mice. Conversely, injection of lysed
CXCR2−/− cells results in reduced neutrophil recruitment as
compared to cell lysates from wild-type mice [69]. However,
mesothelial bone marrow-derived cells cannot only sense IL-
1α but also secrete it upon exposure to lysed cells in vitro [70].
Although IL-1α is known for a fairly long time, the
information about its distinct roles in the in vivo setting in
SIRS is limited since most clinical studies focused on the role
of IL-1β rather than the other subtype IL-1α. Moreover, only
few studies have investigated the isolated eﬀects of either
pIL-α or mature IL-α [63]. With respect to trauma, there
is only a single report available investigating the release of
IL-1α in patients with systemic inflammation after accidental
injury. However, in this study IL-1α was not detectable in
any patient at any time point investigated over a 5-day period
[71]. While this does not necessarily mean that IL-1α is
not systemically released during trauma, the findings might
be based on limitations of the detection assays used two
decades ago. Other possible explanations include unknown
internal clearance mechanisms of systemically released
IL-1α, complex formation with endogenous antagonists or
other inflammatory mediators, or tissue sequestration. In
humans, injection of IL-1 leads to symptoms of systemic
inflammation, including fever, myalgia, arthralgia, and a
lowered pain threshold. Although preclinical studies treating
SIRS and sepsis in mice with IL-1Ra revealed promising
results, it failed to significantly reduce the overall mortality of
sepsis in humans in large double-blind, placebo-controlled
clinical trials [72]. To our knowledge, no clinical studies have
been conducted yet to test the eﬀect of specific blockade of
IL-1α in systemic inflammation after trauma in humans.
In summary, IL-1α fulfills the definition criteria for a dual
function alarmin since it not only functions as a powerful
inductor of systemic inflammation when released into the
extracellular space but also acts as a nuclear transcription fac-
tor. However, although IL-1α represents the first dual func-
tion protein described, its particular role in sterile inflam-
mation and trauma is less thoroughly investigated than
HMGB1, its archetypical partner in crime.
4. Interleukin-33
Due to similarities to IL-1α and HMGB1 with respect to
constitutive, nuclear tissue expression and passive release
after loss of cellular integrity, it has been suggested that IL-33
represents the third dual function protein of the alarmin
family [73]. IL-33 was previously known as nuclear factor
from high endothelial venules (NF-HEV) and was identified
by computational data base analysis as the ligand for ST2
(also known as IL-1RL1), which, until then, was designated
as an orphan receptor [74]. IL-33, the latest member of
the IL-1 cytokine family, is mainly expressed in structural
and lining cells, including endothelial cells, fibroblastic
reticular cells of lymphoid tissues, and epithelial cells of
tissues exposed to the environment [73]. In the absence of
inflammatory stimuli, IL-33 localizes to the nucleus, which
is mediated by the amino terminus of full-length IL-33 [75].
IL-33 was originally considered to be actively released to
the extracellular space after proteolytic cleavage of its pre-
cursor pIL-33 [74]. The active release of IL-33 from macro-
phages can be triggered by PAMPs, such as LPS, while
dendritic cells or mast cells have not been found to be source
of active IL-33 secretion [76]. In contrast to other members
of the IL-1 family, active IL-33 secretion is independent of
caspase-1 and caspase-8 (required for cleavage of pIL-1β
and/or pIL-18) or calpain (required for cleavage of pIL-1α)
[76]. Although recombinant pIL-33 is cleaved by recombi-
nant caspase-1 in vitro [74], the in vivo role of caspase-1
in the cleavage of pIL-33 (full-length IL-33) remains contro-
versial [76].
With respect to its role as a DAMP, it has been
demonstrated that nuclear, full-length IL-33 is biologically
active and can be released following cellular damage [77–79].
It has been suggested that diﬀerent biologically active forms
of IL-33 exist [80, 81]. However, to date the distinct roles of
various forms of IL-33 as well as the corresponding mech-
anisms of release are enigmatic, as are potential posttrans-
lational modifications or environment-dependent func-
tional/conformational alterations of IL-33. Although our
knowledge about IL-33 secretion is limited due to its recent
discovery, passive release of IL-33 from necrotic tissues seems
to be the major pathway since pIL-33 does not exhibit typical
peptide sequences for active secretion, and full-length IL-33
is thought to be the biologically most active form [78]. In line
with this, inactivation of IL-33 through proteolytic cleavage
during apoptosis may limit the release of biologically active
full-length IL-33.
With respect to themechanisms of release and activation/
inactivation of IL-33, various studies reported conflicting
results. Initially, it was believed that IL-33 is activated
through caspase-1-dependent cleavage of pIL-33 into an
active form [74]. However, more recently, it has been demon-
strated that the functional activity of IL-33 is independent of
caspase-1-cleavage and that IL-33 may even be inactivated
by caspase-1 [77, 80]. According to another study, cleavage
of IL-33 into less active forms is presumably mediated by
the proapoptotic caspases-3 and -7, while caspase-1 cleavage
only seems to play a minor role under physiological condi-
tions [78]. Moreover, an alternative splice variant of IL-33
has recently been identified, the functional role of which has
yet to be defined [81].
As a dual function protein, IL-33 is active as a nuclear
transcription factor and as a cytokine. But unlike IL-1α and
HMGB1, IL-33 exerts repressive transcriptional activity
and features some anti-inflammatory properties [82]. IL-33
can activate cells of the innate as well as the adaptive immune
system via interaction with membrane ST2, which, in
particular, is abundantly expressed on the surface of T
helper 2 (Th2) cells and mast cells [83]. Through inter-
action with membrane-bound ST2, IL-33 promotes Th2-
type immune responses, with enhanced production of the
anti-inflammatory cytokines IL-5 and IL-13, drives the
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diﬀerentiation of naı¨ve T cells towards a Th2 phenotype,
and functions as chemotactic factor in Th2 cell mobilization
[84, 85]. On mast cells, IL-33 triggers the production and
release of proinflammatory cytokines and chemokines, such
as IL-1β, IL-6, or TNFα, promotes maturation, and induces
degranulation [79, 86, 87]. Therefore, IL-33 has been
attributed to mediate anaphylactic shock [88]. Further-
more, IL-33 amplifies the polarization of alternatively acti-
vated macrophages, upregulates TLR4, and enhances TLR4-
mediated cytokine production by macrophages [79, 89, 90].
The receptor for IL-33, ST2, exists in diﬀerent splice variants,
resulting in a localized form bound to the cellular membrane
and a soluble form [91]. The soluble variant, termed sST2, is
generated by alternative splicing and is not thought to induce
signaling, therefore acting as a decoy receptor for IL-33 [79].
Similar to IL-33, sST2 has been linked to the pathogenesis of
various inflammatory conditions, including sepsis, asthma,
autoimmune diseases, and cardiovascular diseases [92–95].
In general, sST2 is considered as a marker of poor prognosis.
Since IL-33 represents the most recent member of dual-
function DAMPs, to date there are no specific clinical data
available on the role and kinetics in patients with severe
trauma. However, there is indirect evidence of its involve-
ment in trauma since it has been demonstrated that patients
with SIRS after major trauma or sepsis exhibit elevated
levels of the soluble receptor sST2, possibly associated with
a poor outcome [10]. In contrast to sterile injury and
trauma, the role of IL-33 in sepsis is better defined. In
experimental sepsis, IL-33 has beneficial eﬀects by enhancing
the accumulation of neutrophils at the site of infection and
reducing systemic but not local proinflammatory responses,
resulting in an improved outcome [96]. However, it remains
to be determined in future studies if administration of IL-
33 in fact represents a therapeutic strategy in the clinical
treatment of patients with sepsis or SIRS.
Taken together, the novel cytokine and alarmin IL-33
functions as an important activator of the innate and the
adaptive immune system. However, its particular roles
remain enigmatic to date since, depending on the environ-
ment, IL-33 can either play a beneficial role and lead to the
resolution of inflammatory processes, or, on the other hand,
IL-33 can contribute to aggravation of inflammation.
5. Mitochondrial DAMPs
Bacterial infection and major trauma both can elicit
responses that are summarized as systemic inflammatory
response syndrome (SIRS) or sepsis, respectively [97–99].
The clinically similar phenotype led to the hypothesis that
the molecular pathways may have resemblances as well.
According to the “danger theory,” traumatic cell destruc-
tion causes release of substances that are usually hidden
intracellularly, but signify “danger” to the host once they
appear in the extracellular environment [5]. Searching for
endogenous agents that provoke activation of the immune
response, mitochondria could be recently identified as potent
eﬀectors. Based on striking similarities between bacteria
andmitochondria, the endosymbiotic theory was established
already more than a century ago, according to which bacteria
with the ability to conduct respiration were incorporated
by eukaryotic cells by endocytosis [100]. However, a direct
link between the development of SIRS and the release of
mitochondrial constituents following cellular damage in
trauma could not be established until recently when it has
been shown that mitochondrial DAMPs (MTDs) are
markedly elevated in severely injured patients [101]. These
MTDs mainly comprise circular DNA strands containing
CpG DNA repeats and N-formylated peptides [102].
Mitochondrial DNA (mtDNA) is released by shock and
can directly activate neutrophils after binding to TLR9 [103,
104]. Moreover, proinflammatory cytokine secretion by
monocytes/macrophages was found to be augmented after
exposure to mtDNA [105]. Mitochondrial DNA released
after trauma can directly activate neutrophils after binding to
TLR9 and activation of the intracellular p38 MAPK signaling
pathway [103, 104]. In accord, systemic administration of
mtDNA in mice resulted in systemic inflammation and the
development of lung injury [101]. Therefore, it has been
hypothesized that the release of soluble mitochondrial
degradation products may be the missing link between tissue
injury and sterile SIRS [106]. As an example for the relevance
in the clinical setting, it has been shown that femoral reaming
during fracture fixation causes release of MTDs into the
wound and circulation, which may be associated with the
development of acute lung injury [107].
N-formyl peptides synthesized by mitochondria are
strong chemoattractants as they closely resemble those
derived from bacteria [108]. They bind to formyl-peptide
receptors (FPRs) and its functional variant FPR-like 1 recep-
tor (FPRL1) [109]. It has been demonstrated that isolated
mitochondrial peptide fragments bind to FPRL1 and trig-
ger proinflammatory responses through chemotactic eﬀects
[110]. Especially phagocytic cells, which are specialized in
defending the host against invading microorganisms, express
FPR and FPRL1 on their surface [111]. Signal transduction
through G-proteins following engagement of FPR and
FPRL1 results in chemotaxis, Ca2+ mobilization, activation
of MAP-kinase signaling pathways, cytokine production and
release, desensitization of other chemoattractant receptors,
and respiratory burst [112–115]. Interestingly, isolated N-
formyl peptides do not trigger an inflammatory response in
monocytes unless coupled with mitochondrial transcription
factor A (TFAM), a homologue to the nuclear HMGB1 [116].
These eﬀects of mitochondrial N-formyl peptides can be
attenuated by receptor antagonists or silencing of FPR [116].
With respect to the role in ATP-generation, mitochon-
drial function was found to be reduced in sepsis and trauma
patients, resulting in ATP-depletion and eventually cellular
necrosis [117]. Furthermore, the mitochondrial production
of ROS is enhanced during the inflammatory response in
trauma and sepsis. It has been suggested that mitochondrial
ROS can regulate NF-κB levels in immune cells, thereby
inducing an inflammatory response [117].
Moreover, mitochondria have emerged as crucial medi-
ators in the induction of apoptosis during SIRS in trauma
and shock [117, 118]. Besides this well-known form of pro-
grammed cell death, there is now evidence that necrosis can
also occur in an organized manner, called necroptosis. It can
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be induced by so-called death receptors, such as TNF-R, dur-
ing SIRS and involves activity of the receptor-interacting pro-
tein kinase pathway (RIPK). Activation of RIPK1 and RIPK3,
a signaling complex also referred to as necrosome, is fol-
lowed by active disintegration of mitochondrial and plasma
membranes [119, 120]. In a recent report, RIPK3-deficient
mice were protected from lethality in experimental models
of sterile SIRS and polymicrobial sepsis [119]. Interestingly,
levels of mitochondrial DNA in plasma were lower in RIPK3-
deficient mice, suggesting reduced tissue damage in absence
of RIPK3 [119].
In summary, besides their known functions in ATP-gen-
eration, apoptosis, biosynthesis, and calcium homeostasis,
mitochondria play an important role in activating innate
immunity since they contain constituents of their bacterial
ancestors which are potentially immunogenic [121].
6. Conclusions
The dual-function alarmins HMGB1, IL-1α, and IL-33 rep-
resent crucial mediators in the initiation and perpetuation of
the inflammatory response following loss of cellular integrity.
While HMGB1, IL-1α, and IL-33 share the unique features
of acting as transcription factors and extracellular mediators
of inflammation, each dual-function protein exerts distinct
functions, which we are just beginning to understand. Fur-
ther, the dual-function mediators substantially diﬀer in their
mechanism of action and release. Based on the information
available to date, the role of the dual-function mediators in
systemic inflammation provides a possible explanation for
the enigmatic question of why patients with severe (sterile)
injury present with a syndrome that is indistinguishable from
sepsis. The discovery of mitochondrial DAMPs, which
activate the immune response after cellular disruption by
mimicking bacterial infection, has opened up a new avenue
for the investigation of danger sensing and transmission.
However, future basic science research as well as clinical
studies in this fascinating field are necessary to further
unravel the complexity of the host response after trauma and
tissue damage. In the setting of sterile injury and trauma,
the roles of IL-1α and IL-33 and their various forms as a
result of posttranslational modifications and corresponding
environments need to be defined in detail. In this context,
novel preclinical models of trauma may help characterize
the role of DAMPs and investigate mechanisms/kinetics of
release after tissue injury in single-organ injury and multi-
system trauma, followed by rapid transfer of findings to the
setting of human disease. Further possible future research
directions may include posttranslational modifications of
DAMPs and their dynamics after tissue injury, which may
be associated with alterations of the functional roles, ranging
from activation of inflammation to tissue repair, or even
anti-inflammatory activity. In addition, only little is known
about mutual interactions of DAMPs prior and after passive
or active release and direct crosstalk with other mediators
of inflammation and signaling systems. Moreover, mech-
anisms of intracellular retain of DAMPs during diﬀerent
modalities of cell death appear to be an interesting field
for future research. With respect to potential therapeutic
strategies, besides agents that neutralize or block DAMPs, the
development of compounds that cause intracellular DAMP
retention and limit DAMP release upon tissue damage might
represent a promising approach. The versatility of DAMPs
and associated signaling systems is an impressive example for
the plasticity of innate immunity, and with increasing under-
standing of the underlying mechanisms and interactions,
routine clinical application of DAMP-targeting strategies for
the treatment of patients with SIRS may be in reach.
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